Results 231 to 240 of about 129,945 (312)

Tofacitinib extends survival in a mouse model of ALS through NK cell-independent mechanisms. [PDF]

Front Immunol
Baird LA, Teener SJ, Webber-Davis IF, Carter AD, Huang F, Jang DG, Famie JP, Piecuch CE, Guo K, Feldman EL, Murdock BJ.   +10 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Gasdermins in neurodegeneration: emerging mechanisms and therapeutic targets. [PDF]

Cell Death Dis
Chen S, Zhang J, Chen X, Lai Z, Zhao Z, Wang SB.   +5 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Sterile innate immune mechanisms in neurodegenerative diseases. [PDF]

J Biol Chem
Ealy A, Serapiglia AM, Panicker N.
europepmc   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

The aging factor EPS8 induces disease-related protein aggregation through RAC signaling hyperactivation. [PDF]

Nat Aging
Koyuncu S, Dominguez-Canterla Y, Alis R, Salarzai N, Petrovic D, Flames N, Vilchez D.   +6 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

ATH-1105 mitigates multiple pathologies in ALS models both alone and in combination with riluzole. [PDF]

Front Neurol
Berthiaume AA, Kleist KN, Reda SM, Setti SE, Wu W, Johnston JL, Taylor RW, Stein LR, Church KJ.   +8 more
europepmc   +1 more source